Worldwide News

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in blood cancers, which could have huge implications for […]

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).   Regulatory approval has been received in the US […]

Israeli researchers have developed a drug that is effective in treating a rare genetic muscle disease. The research team from Ben-Gurion University of the Negev and Soroka Medical Center discovered the severe hereditary muscle disease that develops around the age of 40 years, progressing to complete immobility of the limbs and the chest muscles. The […]

SpyBiotech, a UK-based biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.   This project will harness SpyBio’s ‘plug and display’ technology to design a broadly cross-protective […]

This latest ebook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer   Advances and challenges in cancer drug discovery   The ‘dark matter’ behind cancer  The drug that may […]

A new study has found that highly purified gelatin biomaterials could enhance the reliability and reproducibility of 3AD in vitro models, creating new possibilities for replacing preclinical animal trials. The joint study by the University of Twente, The Netherlands, and Rousselot Biomedical investigated for the first time the impact of endotoxins on 3D breast tumour-immune […]

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi.  Pipeline  Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is to develop advanced, long-lasting treatments for dermatological diseases based on […]

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately five collaborative projects that aim to rapidly identify new […]

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological tumours.    The research   PI3Kδ inhibition in solid tumours has […]

A series of new measures will be introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to make it faster and easier to gain approval and run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in over 20 years and are designed to make the […]